The retrial of a lawsuit claiming asbestos supposedly present in Johnson & Johnson's cosmetic talc products caused a 30-year-old attorney to develop mesothelioma begins [November 5, 2018] in South Carolina state court, and the full trial will be webcast live and on demand by Courtroom View Network. A hung jury last May caused an initial … [Read more...]
Differentiating epithelioid mesothelioma from lung adenocarcinoma — MUC21 is a novel, negative immunohistochemical marker
A recent medical study investigated the potential usefulness of mucin 21 (MUC21), as a novel, negative diagnostic marker for purpose of differentiating epithelioid mesothelioma from lung adenocarcinoma. In order to analyze the expression of MUC21 by immunohistochemistry, 70 epithelioid mesothelioma and 70 lung adenocarcinoma cases were examined. … [Read more...]
NY Court of Appeals to Weigh Expert Opinion Linking Asbestos, Mesothelioma
The New York Court of Appeals is set to hear arguments this week on whether expert testimony on the potential link between certain asbestos-containing products and a mechanic’s mesothelioma was enough for a jury to find Ford Motor Co. partly liable for the worker’s illness. The arguments are on an appeal from the Appellate Division, First … [Read more...]
Appellate court requires Reynolds to disclose lists linked to asbestos lawsuit
A three-judge appellate court panel in Pennsylvania ruled Thursday that R.J. Reynolds Tobacco Co. must release lists of smokers and employees who sued Lorillard Inc. related to cigarette filters that contained asbestos. Reynolds inherited the legal liability as part of its $29.25 billion purchase of Lorillard in July 2015. Reynolds could not be … [Read more...]
Zoledronic acid in the management of mesothelioma – a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial
Background: Nitrogen containing bisphosphonates such as zoledronic acid (ZA) are known to contain certain anti-cancer properties. These have been investigated in the past in various cancers such as breast, prostate and colon. ZA in particular has shown promising results in pre-clinical studies. We propose a multicentre double-blind randomised … [Read more...]
Early Signs of Efficacy Seen With Mesothelin CAR T-Cell Therapy
Mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with malignant pleural disease and mesothelioma, non–small cell lung cancer, or breast cancer (NCT02414269). Additionally, significant responses were seen in patients who went on to receive subsequent PD-1 … [Read more...]